Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(139 intermediate revisions by 3 users not shown)
Line 4: Line 4:
 
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
 
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
  
−
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
+
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
  
−
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers, Clinically Feasible Profile. March 28, 2023. doi:10.1148/QIBA/20230328]]
−
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
 
−
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
 
  
−
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
+
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023. doi:10.1148/QIBA/20231219]]
−
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
  
−
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
+
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022. doi:10.1148/QIBA/20220721]]
  
 +
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022. doi:10.1148/QIBA/20221215]]
  
−
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
+
*[[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|MR Elastography of the Liver, Clinically Feasible Profile: ''Maintenance draft''. November 7, 2023. doi:10.1148/QIBA/20231107]]
 +
**[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver, Clinically Feasible Profile. February 2, 2022.]]
  
−
* [[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf|Diffusion-Weighted Magnetic Resonance Imaging (DWI) 2019-12-20]]
+
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid, Clinically Feasible Profile. June 3, 2022. doi:10.1148/QIBA/20220603]]
  
−
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | 18F-labeled PET tracers targeting Amyloid as an Imaging Biomarker 2018-06-20]]  
+
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023. doi:10.1148/QIBA/20230816]]
 +
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.]]
 +
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0. December, 2014.]]
  
−
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]  
+
*[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf| US Shear Wave Speed for Liver Fibrosis, Clinically Feasible Profile. January 15, 2024. doi:10.1148/QIBA/20240115]]
 +
::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E. December 28, 2023]]
 +
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible Site Assessment. January 26, 2023]]
  
−
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1, 2017-06-26]]
+
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
−
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]]
+
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23
 +
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]
  
−
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]]
  
−
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
+
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]
  
 +
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]
  
−
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
+
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]
 +
 
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]
 +
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]
  
−
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
+
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
−
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|Dynamic Susceptibility Contrast MRI (DSC-MRI) Profile 2020-01-29]] (<font color=green>'''Public Comment Open''': March 2 - May 15, 2020<font>)
+
*[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf| US Volume Blood Flow Profile, Consensus version 2024-01-05]]
  
−
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] (<font color=#8b0000>'''closed''' on February 3, 2020<font>)
+
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]
  
−
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]]
  
−
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: QIBA US SWS Checklists for Implementation of the SWS Profile, 2019-10-21]] ('''closed''' on December 18, 2019)
+
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 +
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)
  
−
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
 
  
−
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|QIBA CT Lung Density Protocols-Appendix E, 2019-06-26]] ('''closed''' on October 16, 2019)
+
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.
  
−
*[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] ('''closed''' on June 3rd, 2019)
+
'''Tools to aid Biomarker Committees in collating these comments:'''
 +
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]'''
 +
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]'''
 +
'''
  
  
−
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
+
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''
  
−
==Format for Citing Profiles==
+
 +
====Format for Citing Profiles====
 
Cite QIBA Profile documents as:
 
Cite QIBA Profile documents as:
  
−
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. QIBA, ''Date''. Available from: ''URL''
+
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''
  
 
Example:
 
Example:
  
−
: QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1.  Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
+
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
  
  
−
==Statements of Endorsement==
+
====Statements of Endorsement====
 
*[[Industry]]
 
*[[Industry]]
 
*[[Clinical Sites]]
 
*[[Clinical Sites]]
Line 70: Line 82:
  
  
−
==See Also==
+
====See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Latest revision as of 19:24, 18 April 2024

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Tools to aid Biomarker Committees in collating these comments:


QIBA Profiles and Clinical Applications


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also
Retrieved from "https://qibawiki.rsna.org/index.php?title=Profiles&oldid=19672"